Literature DB >> 31172249

Limited sampling strategy to predict mycophenolic acid area under the curve in pediatric patients with nephrotic syndrome: a retrospective cohort study.

Joanna Sobiak1, Matylda Resztak2, Tomasz Pawiński3, Paweł Żero3, Danuta Ostalska-Nowicka4, Jacek Zachwieja4, Maria Chrzanowska2.   

Abstract

PURPOSE: Limited sampling strategy (LSS) is a precise and relatively convenient therapeutic drug monitoring method. We evaluated LSSs for mycophenolic acid (MPA) in children with nephrotic syndrome treated with mycophenolic mofetil (MMF) and validated the LSSs using two different approaches.
METHODS: We measured MPA plasma concentrations in 31 children using HPLC-UV method and received 37 MPA pharmacokinetic profiles (0-12 h). For six children, MPA profiles were estimated twice after two MMF doses. LSSs were developed using multilinear regression with STATISTICA and R software and validated using validation group and bootstrap method, respectively.
RESULTS: The best three time point equations included C1, C3, C6 (good guess 83%, bias - 2.78%; 95% confidence interval (CI) - 9.85-0.46); C1, C2, C6 (good guess 72%, bias 0.72%; 95% CI - 5.33-7.69); and C1, C2, C4 (good guess 72%, bias 2.05%; 95% CI - 4.92-13.01) for STATISTICA software. For R software, the best equations consisted of C1, C3, C6 (good guess 92%, bias - 2.69%; 95% CI - 27.18-33.75); C0, C1, C3 (good guess 84%, bias - 2.11%; 95% CI - 24.19-22.29); and C0, C1, C2 (good guess 84%, bias - 0.48%; 95% CI - 30.77-54.07). During validation, better results were obtained for R evaluations, i.e., bootstrap method.
CONCLUSIONS: The most useful equations included C0, C1, C3 and C0, C1, C2 time points; however, the most precise included C1, C3, C6 time points because of MPA enterohepatic recirculation. Better results were obtained for bootstrap validation due to greater number of patients. Validated LSS should be used only in the population for which it was developed. As there is growing evidence that underexposure of MPA is associated with insufficient treatment response, we recommend the introduction of therapeutic drug monitoring for MPA in children with nephrotic syndrome.

Entities:  

Keywords:  Limited sampling strategy; Mycophenolic acid; Nephrotic syndrome; Pediatric patients; Pharmacokinetics; Therapeutic drug monitoring

Mesh:

Substances:

Year:  2019        PMID: 31172249     DOI: 10.1007/s00228-019-02701-5

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  31 in total

1.  Limited sampling strategy for predicting area under the concentration-time curve of mycophenolic acid in adult lung transplant recipients.

Authors:  Lillian S L Ting; Nilufar Partovi; Robert D Levy; K Wayne Riggs; Mary H H Ensom
Journal:  Pharmacotherapy       Date:  2006-09       Impact factor: 4.705

2.  Therapeutic mycophenolic acid monitoring by means of limited sampling strategy in orthotopic heart transplant patients.

Authors:  M Baraldo; M Isola; M T Feruglio; A Francesconi; L Franceschi; V Tursi; U Livi; M Furlanut
Journal:  Transplant Proc       Date:  2005-06       Impact factor: 1.066

Review 3.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

4.  Liquid chromatographic determination of mycophenolic acid and its metabolites in human kidney transplant plasma: pharmacokinetic application.

Authors:  Fawzy A Elbarbry; Ahmed S Shoker
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-10-07       Impact factor: 3.205

Review 5.  Steroid withdrawal in pediatric and adult renal transplant recipients.

Authors:  Burkhard Tönshoff; Britta Höcker; Lutz T Weber
Journal:  Pediatr Nephrol       Date:  2005-01-14       Impact factor: 3.714

6.  Validation of an abbreviated pharmacokinetic profile for the estimation of mycophenolic acid exposure in pediatric renal transplant recipients.

Authors:  Lutz T Weber; Britta Hoecker; Victor W Armstrong; Michael Oellerich; Burkhard Tönshoff
Journal:  Ther Drug Monit       Date:  2006-10       Impact factor: 3.681

7.  Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation.

Authors:  Elias David-Neto; Lilian Monteiro Pereira Araujo; Nairo Massakazu Sumita; Maria Elizabeth Mendes; Maria Cristina Ribeiro Castro; Cristiane Feres Alves; Erica Kakehashi; Paschoalina Romano; Elisa Midori Yagyu; Margaret Queiroga; William Carlos Nahas; Luiz Estevam Ianhez
Journal:  Pediatr Nephrol       Date:  2003-02-22       Impact factor: 3.714

8.  Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy.

Authors:  Guido Filler
Journal:  Transpl Int       Date:  2004-01-29       Impact factor: 3.782

9.  Universal approach to pharmacokinetic monitoring of immunosuppressive agents in children.

Authors:  G Filler; J Feber; N Lepage; G Weiler; I Mai
Journal:  Pediatr Transplant       Date:  2002-10

10.  Limited sampling strategy for the estimation of mycophenolic acid area under the plasma concentration-time curve in adult patients undergoing liver transplant.

Authors:  Yu Zicheng; Zhang Weixia; Chen Hao; Chen Hongzhuan
Journal:  Ther Drug Monit       Date:  2007-04       Impact factor: 3.681

View more
  4 in total

1.  Sustained suppression of enterohepatic circulation of mycophenolic acid by antimicrobial-associated diarrhea in a kidney transplant recipient with Crohn's disease: A case report.

Authors:  Ryota Tanaka; Asami Matsumoto; Ryosuke Tatsuta; Tadasuke Ando; Toshitaka Shin; Hiromitsu Mimata; Hiroki Itoh
Journal:  Clin Case Rep       Date:  2022-06-05

2.  A Systematic Review of Multiple Linear Regression-Based Limited Sampling Strategies for Mycophenolic Acid Area Under the Concentration-Time Curve Estimation.

Authors:  Joanna Sobiak; Matylda Resztak
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-09-04       Impact factor: 2.441

3.  The Evaluation of Multiple Linear Regression-Based Limited Sampling Strategies for Mycophenolic Acid in Children with Nephrotic Syndrome.

Authors:  Joanna Sobiak; Matylda Resztak; Maria Chrzanowska; Jacek Zachwieja; Danuta Ostalska-Nowicka
Journal:  Molecules       Date:  2021-06-18       Impact factor: 4.411

Review 4.  Recent Advances in Therapeutic Drug Monitoring of Voriconazole, Mycophenolic Acid, and Vancomycin: A Literature Review of Pediatric Studies.

Authors:  Matylda Resztak; Joanna Sobiak; Andrzej Czyrski
Journal:  Pharmaceutics       Date:  2021-11-23       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.